Johnson & Johnson JNJ Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Sales to customers (Note 9) by Business | ||||||
| Innovative Medicine | $15.43B-2.1% | $15.76B+1.3% | $15.56B+2.4% | $15.2B+9.6% | $13.87B-3.2% | |
| MEDTECH | $8.64B-1.9% | $8.8B+4.4% | $8.43B-1.3% | $8.54B+6.5% | $8.02B-2.1% | |
| Other (income) expense, net by Business | ||||||
| Innovative Medicine | -$12M+93.8% | -$193M+47.6% | -$368M-2,729% | $14M+108% | -$166M+17.4% | |
| MEDTECH | $76M-90.6% | $806M+40,200% | $2M-98.9% | $190M+417% | -$60M-171% | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest by Business | ||||||
| Innovative Medicine | $5.32B+5.1% | $5.06B-21.5% | $6.45B+16.1% | $5.55B+6.6% | $5.21B+30.0% | |
| MEDTECH | $1.24B+516% | $201M-84.4% | $1.29B+6.9% | $1.2B-15.3% | $1.42B+1,874% | |
| Total Assets by Business | ||||||
| General Corporate | $36.6B+5.6% | $34.67B+8.7% | $31.89B+2.4% | $31.16B-37.5% | $49.83B+28.7% | |
| Innovative Medicine | $78.12B+0.1% | $78.06B+4.9% | $74.42B-1.4% | $75.49B+28.5% | $58.73B+2.9% | |
| MEDTECH | $86.18B-0.4% | $86.48B0.0% | $86.5B-0.3% | $86.75B+1.9% | $85.11B+0.9% | |
| Cost of products sold by Business | ||||||
| Innovative Medicine | $4.39B+10.4% | $3.98B+8.3% | $3.67B-7.7% | $3.98B-1.0% | $4.02B+14.4% | |
| MEDTECH | $3.7B-6.8% | $3.97B+10.0% | $3.61B-0.7% | $3.64B+9.4% | $3.33B-7.5% | |
| Depreciation and Amortization by Business | ||||||
| General Corporate | $65M-7.1% | $70M+18.6% | $59M-1.7% | $60M+15.4% | $52M-16.1% | |
| Innovative Medicine | $1.04B+2.1% | $1.02B+22.0% | $832M-20.1% | $1.04B+17.8% | $884M-8.6% | |
| MEDTECH | $903M-2.5% | $926M+4.5% | $886M+5.2% | $842M+0.7% | $836M-3.6% | |
| Selling, marketing and administrative expenses by Business | ||||||
| Innovative Medicine | $2.92B-15.6% | $3.46B+20.5% | $2.87B+2.9% | $2.79B+23.4% | $2.26B-31.7% | |
| MEDTECH | $2.91B-4.3% | $3.04B+8.4% | $2.8B-2.1% | $2.86B+7.8% | $2.66B-6.3% | |
| Research and development expense by Business | ||||||
| Innovative Medicine | $2.81B-18.8% | $3.47B+17.7% | $2.94B+2.6% | $2.87B+12.6% | $2.55B-31.1% | |
| MEDTECH | $714M-9.2% | $786M+8.0% | $728M+12.5% | $647M-4.4% | $677M-57.7% | |
| Additions to Property, Plant & Equipment by Business | ||||||
| General Corporate | $32M-68.0% | $100M+33.3% | $75M+82.9% | $41M+5.1% | $39M-33.9% | |
| Innovative Medicine | $508M-44.2% | $910M+90.0% | $479M+16.5% | $411M+48.9% | $276M-62.7% | |
| MEDTECH | $509M-38.5% | $827M+37.1% | $603M+2.0% | $591M+23.1% | $480M-41.0% | |
| Goodwill, Written off Related to Sale of Business Unit by Business | ||||||
| Innovative Medicine | $0— | $0— | $0— | $0— | $0— | |
| MEDTECH | $0— | —— | —— | —— | $29M— | |
| Percent Change (as a percent) by Business | ||||||
| Innovative Medicine | 32%+31.1pp | 0.9%-20.4pp | 21.3%-2.7pp | 24%+1.7pp | 22.3%+31.5pp | |
| MEDTECH | 18.5%— | —— | 21.2%-2.3pp | 23.5%+7.1pp | 16.4%+15.6pp | |
| Goodwill (Note 3) by Business | ||||||
| Innovative Medicine | $14.81B-1.0% | $14.97B+4.9% | $14.27B-0.4% | $14.33B+31.3% | $10.91B+2.0% | |
| MEDTECH | $33.75B-0.2% | $33.81B+0.1% | $33.78B0.0% | $33.79B+0.7% | $33.56B+0.2% | |
| Currency translation/Other by Business | ||||||
| Innovative Medicine | -$155M-372% | $57M— | $0-100% | $543M+153% | $215M+149% | |
| MEDTECH | -$59M-336% | $25M— | $0-100% | $230M+180% | $82M+145% | |
| Goodwill, related to acquisitions by Business | ||||||
| Innovative Medicine | $0-100% | $642M— | $0-100% | $2.88B— | $0-100% | |
| MEDTECH | $0— | $0— | $0— | $0— | $0-100% | |
| Amortization by Business | ||||||
| Innovative Medicine | $800M— | —— | $600M-25.0% | $800M+33.3% | $600M— | |
| MEDTECH | $500M— | —— | $500M0.0% | $500M0.0% | $500M— | |
| Sales to customers (Note 9) by Product | ||||||
| ADVANCED | $1.12B-4.4% | $1.18B+0.9% | $1.17B+0.1% | $1.16B+8.5% | $1.07B-6.8% | |
| CAPLYTA | $270M+8.4% | $249M+3.8% | $240M+13.7% | $211M— | $0— | |
| CARVYKTI | $597M+7.6% | $555M+5.9% | $524M+19.4% | $439M+19.0% | $369M+10.5% | |
| CONCERTA/Methylphenidate | $136M+3.0% | $132M-5.7% | $140M-14.6% | $164M+10.8% | $148M-6.9% | |
| CONTACT LENSES / OTHER | $969M-3.9% | $1.01B-1.0% | $1.02B+5.5% | $965M+5.0% | $919M-1.9% | |
| DARZALEX | $3.96B+1.6% | $3.9B+6.3% | $3.67B+3.8% | $3.54B+9.3% | $3.24B+5.0% | |
| EDURANT/rilpivirine | $409M+6.8% | $383M-0.5% | $385M+6.9% | $360M+0.6% | $358M+11.2% | |
| ERLEADA | $949M-1.0% | $959M+2.5% | $936M+3.1% | $908M+17.8% | $771M-1.7% | |
| GENERAL | $1.39B-5.4% | $1.47B+6.5% | $1.38B-0.9% | $1.39B+5.1% | $1.32B-2.5% | |
| HIPS | $436M-0.7% | $439M+8.4% | $405M-3.8% | $421M+2.9% | $409M-2.2% | |
| IMBRUVICA | $660M-3.5% | $684M-1.6% | $695M-5.4% | $735M+3.7% | $709M-3.0% | |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | $1.04B+5.3% | $986M+6.1% | $929M-6.4% | $992M+9.9% | $903M-15.1% | |
| KNEES | $420M-2.8% | $432M+14.6% | $377M-3.1% | $389M0.0% | $389M-2.3% | |
| OPSUMIT/OPSYNVI | $606M— | —— | $578M-0.7% | $582M+11.5% | $522M— | |
| OTHER IMMUNOLOGY | $46M+15.0% | $40M+233% | $12M+50.0% | $8M+700% | $1M— | |
| OTHER INFECTIOUS DISEASES | $37M-7.5% | $40M-14.9% | $47M0.0% | $47M+14.6% | $41M-8.9% | |
| OTHER NEUROSCIENCE | $262M+6.9% | $245M-4.3% | $256M-5.2% | $270M-2.5% | $277M+8.6% | |
| Other Oncology | $192M+92.0% | $100M+6.4% | $94M+1.1% | $93M-56.5% | $214M+185% | |
| Other | $2.9B+1,064% | $249M-5.7% | $264M-14.6% | $309M-89.1% | $2.84B+911% | |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | $443M+15.7% | $383M-3.5% | $397M+0.3% | $396M-1.7% | $403M-1.0% | |
| Remicade | $422M+14.1% | $370M-22.3% | $476M+4.6% | $455M-2.6% | $467M+30.1% | |
| RYBREVANT + LAZCLUZE | $257M+19.0% | $216M+9.1% | $198M+10.6% | $179M+27.0% | $141M+15.6% | |
| SIMPONI / SIMPONI ARIA | $647M+2.4% | $632M-8.0% | $687M-0.4% | $690M+4.7% | $659M+13.0% | |
| SPINE & OTHER | $694M— | —— | $698M-4.0% | $727M+8.3% | $671M— | |
| SPRAVATO | $468M-7.0% | $503M+9.6% | $459M+10.9% | $414M+29.4% | $320M+7.7% | |
| STELARA | $656M-46.7% | $1.23B-21.7% | $1.57B-5.0% | $1.65B+1.7% | $1.63B-30.8% | |
| SURGICAL | $396M-3.6% | $411M+7.3% | $383M-5.0% | $403M+11.6% | $361M-1.1% | |
| TALVEY | $152M+2.0% | $149M+22.1% | $122M+15.1% | $106M+23.3% | $86M+1.2% | |
| Tecvayli | $202M+14.8% | $176M-0.6% | $177M+6.6% | $166M+9.9% | $151M+3.4% | |
| TRAUMA | $833M+2.5% | $813M+2.5% | $793M+3.3% | $768M-0.5% | $772M+1.0% | |
| Tremfya | $1.61B+1.2% | $1.59B+11.6% | $1.42B+20.1% | $1.19B+24.1% | $956M+0.7% | |
| UPTRAVI | $483M-1.6% | $491M+1.4% | $484M+1.7% | $476M+5.5% | $451M-3.0% | |
| XARELTO | $642M-6.6% | $687M+8.2% | $635M+2.3% | $621M-10.0% | $690M+2.1% | |
| Percent Change (as a percent) by Product | ||||||
| ADVANCED | 4.6%+4.5pp | 0.1%-4.9pp | 5%+3.0pp | 2%+3.2pp | -1.2%— | |
| CAPLYTA | 0%— | 0%— | 0%— | 0%— | 0%— | |
| CARVYKTI | 62.1%+55.8pp | 6.3%-77.2pp | 83.5%— | —— | —— | |
| CONCERTA/Methylphenidate | -8%-5.3pp | -2.7%-1.3pp | -1.4%-1.6pp | 0.2%+16.5pp | -16.3%— | |
| CONTACT LENSES / OTHER | 5.5%+4.5pp | 1%-4.2pp | 5.2%+0.1pp | 5.1%+4.1pp | 1%-0.7pp | |
| DARZALEX | 22.5%+21.2pp | 1.3%-20.4pp | 21.7%-1.3pp | 23%+2.7pp | 20.3%+19.8pp | |
| EDURANT/rilpivirine | 14.1%+13.3pp | 0.8%-15.6pp | 16.4%-5.2pp | 21.6%+10.9pp | 10.7%— | |
| ERLEADA | 23.1%+21.9pp | 1.2%-17.2pp | 18.4%-5.0pp | 23.4%+11.5pp | 11.9%— | |
| GENERAL | 4.9%+3.4pp | 1.5%-2.4pp | 3.9%+0.6pp | 3.3%+3.8pp | -0.5%-0.3pp | |
| HIPS | 6.5%+5.7pp | 0.8%-5.6pp | 6.4%+5.4pp | 1%+4.1pp | -3.1%— | |
| IMBRUVICA | -6.9%— | —— | -7.8%-3.3pp | -4.5%+5.0pp | -9.5%-9.4pp | |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | 15%— | —— | -11.3%-5.4pp | -5.9%+8.6pp | -14.5%-15.3pp | |
| KNEES | 7.9%+5.9pp | 2%-5.0pp | 7%+8.1pp | -1.1%+1.9pp | -3%— | |
| OPSUMIT/OPSYNVI | 16.1%— | —— | -0.8%-7.2pp | 6.4%+6.9pp | -0.5%— | |
| OTHER INFECTIOUS DISEASES | -10.4%— | —— | -17.5%+62.3pp | -79.8%-32.2pp | -47.6%-34.6pp | |
| OTHER NEUROSCIENCE | -5.4%— | —— | -8.9%-0.5pp | -8.4%+11.2pp | -19.6%-15.2pp | |
| Other Oncology | -10.6%-15.1pp | 4.5%-5.2pp | 9.7%-2.0pp | 11.7%-10.0pp | 21.7%+119pp | |
| Other | -27.8%— | —— | -13.1%+3.8pp | -16.9%-9.7pp | -7.2%-7.0pp | |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | 10%— | —— | -11.6%-2.2pp | -9.4%-5.7pp | -3.7%— | |
| Remicade | -9.5%— | —— | 13.6%-2.3pp | 15.9%+8.4pp | 7.5%+8.7pp | |
| RYBREVANT + LAZCLUZE | 82.7%— | —— | 99.7%— | —— | —— | |
| SIMPONI / SIMPONI ARIA | -1.7%— | —— | 32.9%+4.3pp | 28.6%+9.7pp | 18.9%— | |
| SPINE & OTHER | 3.5%— | —— | 0.3%+2.4pp | -2.1%+8.7pp | -10.8%— | |
| SPRAVATO | 46.4%+42.0pp | 4.4%-57.1pp | 61.5%+8.2pp | 53.3%+11.4pp | 41.9%— | |
| STELARA | -59.7%-57.9pp | -1.8%+39.5pp | -41.3%+1.4pp | -42.7%-9.0pp | -33.7%-30.3pp | |
| SURGICAL | 9.7%+8.9pp | 0.8%-14.1pp | 14.9%+5.0pp | 9.9%+6.2pp | 3.7%+0.8pp | |
| TALVEY | 76.7%+70.7pp | 6%-54.8pp | 60.8%+5.8pp | 55%+6.6pp | 48.4%— | |
| Tecvayli | 33.5%— | —— | 31.3%+8.2pp | 23.1%+9.8pp | 13.3%— | |
| TRAUMA | 8%+6.9pp | 1.1%-3.1pp | 4.2%+3.0pp | 1.2%+0.3pp | 0.9%+0.7pp | |
| Tremfya | 68.3%+58.8pp | 9.5%-31.8pp | 41.3%+10.3pp | 31%+12.8pp | 18.2%— | |
| UPTRAVI | 7.1%+6.7pp | 0.4%-5.2pp | 5.6%-6.1pp | 11.7%+15.3pp | -3.6%— | |
| XARELTO | -7%— | —— | 7.4%+1.8pp | 5.6%-27.7pp | 33.3%+25.2pp | |
| Sales to customers (Note 9) by Geography | ||||||
| Asia-Pacific, Africa | $3.59B+2.6% | $3.5B-3.2% | $3.61B+0.2% | $3.61B+8.9% | $3.31B+1.6% | |
| Europe | $5.85B+4.5% | $5.6B+2.9% | $5.44B+1.0% | $5.39B+5.4% | $5.11B+3.8% | |
| United States | $13.33B-6.1% | $14.2B+3.6% | $13.71B+1.2% | $13.54B+10.1% | $12.31B-6.8% | |
| Western Hemisphere, excluding U.S. | $1.29B+1.7% | $1.27B+3.2% | $1.23B+2.1% | $1.21B+3.3% | $1.17B+2.8% | |
| Percent Change by Geography | ||||||
| Asia-Pacific, Africa | 8.5%— | —— | 4%-0.4pp | 4.4%+7.2pp | -2.8%— | |
| Europe | 14.5%— | —— | 10.7%+7.4pp | 3.3%+4.3pp | -1%— | |
| United States | 8.3%— | —— | 6.2%-1.6pp | 7.8%+1.9pp | 5.9%— | |
| Western Hemisphere, excluding U.S. | 10.8%— | —— | 4.9%+5.4pp | -0.5%+1.8pp | -2.3%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Johnson & Johnson break its business down?
- Johnson & Johnson (JNJ) reports sales to customers (note 9) by business across 2 parts — Innovative Medicine and MEDTECH. Each is extracted from the segment footnotes and tracked over time.
- Where does Johnson & Johnson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Johnson & Johnson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
